Vigonvita Life Sciences Co., Ltd. (HKG:2630)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Pharmaceuticals	102.10M	11.83M	199.65M
Total	102.10M	11.83M	199.65M

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
People's Republic of China (PRC)	101.94M	11.79M	198.98M
Uzbekistan	156.00K	42.00K	674.00K
Total	102.10M	11.83M	199.65M

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error